FDA approves Amgen's Imdelltra (tarlatamab) for advanced small cell lung cancer, marking first significant progress in decades.

The FDA has approved Amgen's drug, Imdelltra (tarlatamab), for advanced small cell lung cancer (SCLC) patients who have already exhausted other treatment options. The drug tripled the median survival of patients in clinical trials, with 40% of them responding to the treatment. This marks the first significant progress in treating SCLC, a rapidly growing and aggressive form of lung cancer, in decades.